A Prospective Sub-Study of the Global Hypophosphatasia Registry
Study Identifier:
ALX-HPP-501s
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
Recruiting
Study Details
Medical Condition
- Unmapped
Study Drug
- Biological: Asfotase Alfa
Date
Aug 2022 - Aug 2029
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: N/A - N/A
Requirements Information
Sex
Female & Male
Age
N/A - N/A
Study Details
Medical Condition
- Unmapped
Study Drug
- Biological: Asfotase Alfa
Date
Aug 2022 - Aug 2029
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: N/A - N/A years
Requirements Information
Protocol Summary
In this prospective observational sub-study, participants with pediatric-onset hypophosphatasia (HPP) (perinatal/infantile- or juvenile-onset) of any age will be followed for a minimum of 5 years at sites in the United States and potentially 1 or 2 other countries.
Trial Locations
Location
Status
Location
Clinical Trial Site
Hartford, Connecticut, United States, 06106
Status
Recruiting
Location
Clinical Trial Site
Chicago, Illinois, United States, 60611
Status
Recruiting
Location
Clinical Trial Site
Boston, Massachusetts, United States, 02122
Status
Recruiting
Location
Clinical Trial Site
Kansas City, Missouri, United States, 64108
Status
Recruiting
Location
Clinical Trial Site
Mineola, New York, United States, 11501
Status
Recruiting
Location
Clinical Trial Site
Cincinnati, Ohio, United States, 45229
Status
Not yet recruiting